[Incidence of recurrence after primary pterygium excision, phototherapeutic keratectomy with the ArF:Excimer laser and local mitomycin C administration].
BACKGROUND
In this clinical trial the recurrence-rate after primary pterygium-excision, phototherapeutic keratectomy with the ArF:excimerlaser and local application of mitomycin C should be estimated.


METHODS
Forty eyes of 38 patients underwent primary pterygium-excision using a bare-sclera technique. All patients underwent phototherapeutic keratectomy (PTK) with the ArF:excimerlaser of the wound region. Postoperative all patients were treated with mitomycin C 0.02% twice daily for four days and for 4-6 weeks with a combination of gentamycin and dexametason eye drops triple a day. Minimum follow-up was 24 month (median 41 month).


RESULTS
Two eyes developed a recurrence after 12 and 28 month respectively. The overall recurrence rate was 5% (corneal recurrence 2.5%). One patient developed a minute granuloma in the area of the excision. There were no other complications during the follow-up.


CONCLUSIONS
The excision of pterygium using the bare-sclera technique, phototherapeutic keratektomy und local application of mitomycin C 0.02% eye drops is a safe method with a low recurrence-rate. All recurrences occured after more than one year postoperatively.
Walkow
T
T
Augenklinik im Virchow-Klinikum, Medizinische Fakultät, Humboldt-Universität zu Berlin.
Anders
N
N
Antoni
H J
HJ
Wollensak
J
J
D000328:Adult; D000368:Aged; D000903:Antibiotics, Antineoplastic / Q000008:administration & dosage*; D003131:Combined Modality Therapy; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D054018:Lasers, Excimer; D008297:Male; D008875:Middle Aged; D016685:Mitomycin / Q000008:administration & dosage*; D018903:Photorefractive Keratectomy; D011625:Pterygium / Q000188:drug therapy / Q000601:surgery*; D012008:Recurrence
D000903:Antibiotics, Antineoplastic; D016685:Mitomycin
Die Rezidivhäufigkeit nach primärer Pterygiumexzision, phototherapeutischer Keratektomie (PTK) mit dem ArF:Excimerlaser und lokaler Mitomycin-C-Applikation.